v3.26.1
Condensed Statements of Cash Flows (Unaudited) - USD ($)
 6 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating activities    
Net loss $ (3,819,912) $ (485,285)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:    
Amortization and depreciation 125,552 130,761
Stock-based compensation 701,390 589,394
Amortization of deferred offering costs 192,647
Non-cash lease expense 58,420 55,156
Fair value change in warrant liability (214,469) (779,796)
Debt termination costs reclassed to financing activities 132,091
Change in assets and liabilities:    
Accounts receivable (632,578) (142,144)
Inventory 127,390 800,546
Prepaid expenses (142,344) 8,394
Accounts payable (59,752) 80,885
Accrued expenses, operating leases and other liabilities (588,243) (430,744)
Net cash (used in) provided by operating activities (4,444,546) 151,905
Investing activities    
Purchase of property and equipment (79,270) (27,587)
Net cash used in investing activities (79,270) (27,587)
Financing activities    
Proceeds from issuance of common stock attributed to equity financings 670,400 414,037
Issuance costs related to equity financings (261,832)
Financing costs in connection with debt facility (297,942)
Deferred issuance costs in connection with at-the-market offering program (22,920)
Exercise of warrants 174,374
Share repurchases for the payment of employee taxes (64,409) (118,372)
Net cash provided by (used in) financing activities 757,445 (264,109)
Net decrease in cash and cash equivalents (3,766,371) (139,791)
Cash and cash equivalents at beginning of period 6,570,382 1,460,042
Cash and cash equivalents at end of period 2,804,011 1,320,251
Supplemental non-cash financing and investing transactions:    
Change in unpaid issuance costs 22,920 72,377
Modification of right-of-use asset and associated lease liability 111,898
Purchased property and equipment in accounts payable 6,499 10,026
Cashless exercise of warrants 87,188
Reclass of warrant liability to equity upon exercise $ 342,918